<DOC>
	<DOCNO>NCT01908140</DOCNO>
	<brief_summary>The purpose study compare efficacy , safety tolerability aclidinium bromide/formoterol fumarate salmeterol/fluticasone propionate patient chronic obstructive pulmonary disease ( COPD )</brief_summary>
	<brief_title>Study Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Adult male nonpregnant , nonlactating female age ≥40 . Current excigarette smoker , smoke history least 10 packyears Patients clinical diagnosis COPD accord GOLD guideline 2013 , postbronchodilator FEV1 &lt; 80 % , FEV1/FVC &lt; 70 % Screening Visits Symptomatic patient COPD assessment test ( CAT ) ≥10 Screening Randomisation Visits Patient must able perform repeatable pulmonary function test FEV1 accord ATS/ERS 2005 criterion Screening Visits Patients eligible able participate trial consent write purpose nature investigation explain History current diagnosis asthma Development respiratory tract infection COPD exacerbation within 6 week ( 3 month hospitalisation require ) Screening Visit runin period Clinically significant respiratory condition Type I uncontrolled Type II diabetes , uncontrolled hypo hyperthyroidism , hypokalaemia , hyperadrenergic state , uncontrolled untreated hypertension Patients , investigator 's opinion , may need start pulmonary rehabilitation programme study and/or patient started/finished within 3 month prior Screening Visit Use longterm oxygen therapy ( ≥15 hours/day ) Patients treated daily basis triple therapy ( LABA+LAMA+ICS ) within 4 week prior Screening Visit Patient maintain regular day/night , waking/sleeping cycle include night shift worker Clinically significant cardiovascular condition Patient clinically relevant abnormality result clinical laboratory test , ECG parameters physical examination Screening Visit Patient history hypersensitivity reaction inhale anticholinergic , sympathomimetic amine , inhaled medication component thereof ( include report paradoxical bronchospasm ) Patient know narrowangle glaucoma , symptomatic bladder neck obstruction , acute urinary retention , patient symptomatic nonstable prostatic hypertrophy Patient know noncontrolled history infection human immunodeficiency virus ( HIV ) and/or active hepatitis History malignancy organ system ( include lung cancer ) , treat untreated , within past 5 year basal squamous cell skin cancer Patient serious uncontrolled physical mental dysfunction Patient history ( within 2 year prior Screening Visit ) drug and/or alcohol abuse may prevent study compliance base investigator judgment Patient unlikely cooperative ca n't comply study procedure Patient treat investigational drug within 30 day ( 6 halflives , whichever long ) prior Screening Visit Patient intend use concomitant medication permit protocol undergone require stabilization period prohibit medication Any condition , investigator 's opinion , might indicate patient unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>